McGarvey, November http://orcid.org/0000-0003-4439-4788
Ung, Brian
Carattini, Thomas
Imanak, Ken
Lee, Abraham
Campbell, Timothy B.
Patwardhan, Pallavi
Funding for this research was provided by:
Bristol-Myers Squibb
2seventy bio
Article History
Received: 7 April 2023
Accepted: 19 July 2023
First Online: 19 August 2023
Declarations
:
: November McGarvey, Ken Imanak, and Abraham Lee are employees of BluePath Solutions, which received funding for this research from Bristol Myers Squibb. Thomas Carattini, Timothy B. Campbell, and Pallavi Patwardhan are employees and shareholders of Bristol Myers Squibb. Brian Ung was an employee of Bristol Myers Squibb at the time that the study was conducted and is now employed by Sarepta Therapeutics.
: This study does not contain any new analyses conducted by the authors with human participants or animals. The primary KarMMa study was conducted in accordance with the International Council for Harmonization guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. The study protocol was approved by local or independent institutional review boards or ethics committees at participating sites. All the patients provided written informed consent. The authors had permission to access and use the clinical trial database for this study. The efficacy and safety data from the KarMMa clinical trial along with the patient reported outcomes have been previously published [CitationRef removed, CitationRef removed, CitationRef removed].